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Summary
Purpose: Fenretinide, a synthetic form of retinoid, induced apoptosis even in chemotherapy resistant cell lines. A phase II
study was hence conducted to evaluate toxicity and efficacy of fenretinide in metastatic renal cancer. Methods: Eligibility
included unresectable or metastatic renal cell carcinoma (RCC), adequate organ function and Zubrod performance status
≤2. Prior immunotherapy and a maximum of one prior chemotherapy regimen were allowed. Fenretinide was administered
at a dose of 900 mg/m2 twice daily orally for 7 days in a 21-day cycle. Toxicity was assessed at the start of each cycle,
and response every 2 cycles. Results: Nineteen eligible patients enrolled of which fifteen had visceral/bone metastases.
Seventeen patients had prior nephrectomy and 11 had prior immunotherapy. 76 cycles of therapy were delivered. Therapy
was very well tolerated with few severe toxicities consisting of thrombosis in 1 individual and grade 3 fatigue, nausea and
diarrhea in 1 patient. 5 patients had grade 2 nyctalopia and 3 patients had transient grade 2 visual toxicity. No objective
responses were noted. Stable disease was seen in seven of nineteen cases (37%, 90% C.I. 0.21–0.59). Median time to
progression was 1.5 months and median duration of stable disease was 5.8 months (90% C.I. 3.0–8.4). Median survival
was 10 months. Tumor fenretinide levels were obtained in three patients and were in the lower end of the therapeutic
range. Conclusion: Fenretinide was well tolerated but demonstrated minimal activity that was consistent with results of
intratumoral drug measurements. Strategies are needed that will increase systemic and tumor levels of fenretinide.
Introduction
Retinoids are used in cancer therapy for their unique
differentiation properties and their numerous roles in
cellular function. All-trans retinoic acid is indicated in
acute promyelocytic leukemia to differentiate blasts and
facilitate the efficacy of chemotherapy [1]. Retinoids
are vitamin A derivatives that exert a therapeutic effect
in acute promyelocytic leukemia and preclinical anti-
proliferative effects in a variety of other malignancies
such as breast, prostate and lung cancer [1, 2]. Experi-
mental data in renal cancer cell lines suggested that 13-cis
retinoic acid (13-CRA) augments the antiproliferative
effect of interferon in interferon sensitive cell lines [3].
A phase II trial in advanced RCC with interferon and
13-CRA showed a 30% response rate and three complete
responses. A randomized trial comparing 13-CRA and
interferon with interferon alone demonstrated a higher
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response rate in the combination arm (12% vs. 6%) but
no difference in overall survival [4].
Fenretinide (NSC 374551, N-4-hydroxyphenyl reti-
namide, 4-HPR) is a synthetic retinoid that induces apop-
tosis and necrosis in tumor cells, including those that are
unresponsive to retinoic acid [5]. Increase in reactive oxy-
gen species mediating tumor cell death was also observed
in retinoblastoma cell lines [6]. Clinically, fenretinide is
better tolerated and long term administration is feasible
[7]. Chemopreventive trials have been performed in breast
and oral cancers at doses of 200 mg daily [8, 9]. A phase
I study of fenretinide at our institution demonstrated the
maximum tolerated dose of this agent as 1800 mg/m2
daily in two divided doses administered orally for 7 days
in a 21-day cycle. One patient with metastatic renal car-
cinoma had an impressive clinical response. Based on
the preclinical and clinical data of retinoids in renal car-
cinoma, and our experience with fenretinide, a phase





The eligibility criteria consisted of locally advanced un-
resectable, locally recurrent or metastatic RCC with no
prior retinoid therapy. Treatment with biologic therapy
and a maximum of one prior chemotherapy regimen were
permitted. Concomitant administration of antioxidants
was prohibited. All patients had to have unidimension-
ally measurable disease and pre study imaging for dis-
ease assessment within 28 days of registration. A Zubrod
performance status of 0–2 was required. Patients had to
have adequate bone marrow, liver (serum bilirubin, al-
kaline phosphatase and transaminases ≤ twice institu-
tional upper limit of normal) and renal function (serum
creatinine ≤ 2 mg/dL). Prior radiation therapy was al-
lowed, if completed at least four weeks prior to enroll-
ment and only if there was measurable disease outside
the radiation therapy port. Patients with brain metastases
were excluded unless completely resected or irradiated
resulting in a complete response. Individuals with a his-
tory of night blindness or retinal disease were excluded.
No prior malignancy was allowed, except non-melanoma
skin cancer, in-situ carcinoma of any site or other cancers
for which the patient had been disease free for a mini-
mum of two years. Pregnant and lactating females were
excluded due to the possible teratogenic potential of the
study medication. Patients in the reproductive age group
had to practice effective contraception. All patients signed
a written informed consent.
Treatment plan
The fenretinide was administered orally on an outpatient
basis at a dose of 1800 mg/m2/day rounded to the near-
est 100 mg in two divided doses daily for 7 days, every
21 days. The fenretinide was available as 100 mg cap-
sules and patients were instructed to take the medication
with a fatty meal (usually whole milk) to improve the
bioavailability. Compliance was monitored on the basis
of calendars completed by patients. A dose decrease to
1400 mg/m2/day was recommended if any toxicity grade
2 or higher occurred, and the next cycle of drug adminis-
tration was restarted only after resolution of the toxicity
to grade 1 or less.
Measurement of fenretinide in tumor tissue
Collection of tumor biopsies
On day 8 of the first cycle of therapy, tumor samples were
collected via open biopsy (minimum size, 0.5 × 0.5 cm;
maximum size, 1 × 1 cm) or core biopsy (minimum: 4
cores with 14 guage needle), as deemed appropriate by
the surgeon. The biopsy was not mandatory and patients
willing to undergo it signed a separate written informed
consent. The tissue was placed into 1 cc saline containing
butylated hydroxytoluene (BHT), frozen on dry ice, and
stored at −80◦C until HPLC analysis. The BHT stabilizes
the fenretinide against oxidation during storage.
Extraction of fenretinide from tumor tissue
To a 0.5 g tumor biopsy specimen, an equal amount of
refrigerated saline and 50 µL of 40 mg/mL of BHT in
acetonitrile were added and the specimen was homoge-
nized. The homogenate was deproteinated by adding an
equal volume of refrigerated acetonitrile and clarified by
microcentriguation at 10,000 rpm for 10 min at 4◦C. A
150 µL aliquot of supernatant was transferred into the
small volume insert of an HPLC vial and 100 µL injected
into the HPLC.
HPLC analysis
A modified reversed phase liquid chromatographic (LC)
method reported in the literature was used to quantify
fenretinide [10]. Briefly, the method consisted of a Wa-
ters Resolve Spherical C-18 column, 150 × 3.9 mm and
5 µm particle size column fitted with a guard column
(Waters Resolve Spherical C-18, 5 µm, Waters Corpora-
tion, USA). The mobile phase consisted of a mixture of
acetonitrile: water: acetic acid (75:23:2), at a flow rate
of 1 ml/min. The eluent was monitored at 365 nm to
detect the analyte. The concentration of analyte in tu-
mor was determined by back calculation from a linear
regression equation developed from external reference
standards. Application of this method to measurement of
fenretinide in homogenates of skin biopsies and of tumors
from preclinical models has shown that fenretinide recov-
ery is quantitative (data not shown). The LC method was
reproducible, with low inter-day variability (<4%), and
the limit of quantitation under the described conditions
was 50 ng per mL of tumor homogenate.
Response and toxicity evaluation
Toxicity was assessed at the beginning of each cycle of
therapy and response was evaluated every two cycles. The
toxicities were graded as per the National Cancer Insti-
tute Common Toxicity Criteria, Version 2.0. The toxicities
were recorded based on the greatest severity that occurred
at any time during the treatment. The RECIST response
criteria were utilized for assessment of response [11].
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Statistical methods
This phase II trial was planned with a Simon optimal two-
stage design [12]. We wished to distinguish these regions
of the true, unknown (complete + partial) response rate:
0.10 or less versus 0.30 or more. The 2-stage design called
for a maximum of 35 response-evaluable (r-e) patients, 18
in Stage 1 and 17 in Stage 2. The design had type I error of
0.05 and power of 0.90. We needed at least 3 responders
among the first 18 r-e patients to justify beginning Stage 2.
After 20 entries (over 17 months), we had 18 r-e patients.
With no confirmed (partial) responders, the trial was ter-
minated after the first stage was completed. Thus, after
Stage 1, we concluded that the r-e sample response pro-
portion (0/18 = 0%) better supported the null hypothesis
that the true, unknown response rate was at most 0.10.
Exact, minimum-width 90% confidence intervals (CI)
for response, stable disease, and toxicity rates were cal-
culated using the Casella method [13], as implemented in
StatXact software [14]. Standard Kaplan-Meier estimates
of the censored overall survival (OS), time to progression
(TTP), and stable disease duration (SDD) functions were
computed. The toxicity evaluable population was the 19
patients who received any fenretinide treatment, whether
eligible or not, to provide the most complete toxicity data
from this trial. The time to event evaluable population was
the 19 eligible patients, whether treated or not. Due to the
small sample sizes, survival statistics (e.g., median) were
estimated more conservatively using linear interpolation
[15] among successive event times on the Kaplan-Meier
curves. Duration of response or disease stabilization was
measured from the start of therapy to progression or death.
Overall survival was measured from the time of enroll-
ment on the study to death or last follow-up.
Results
Patient characteristics
Twenty patients were enrolled on this study from
December 2000 to May 2002. One patient was deemed
ineligible after the pathology review indicated renal onco-
cytoma histology. The median age of the patients was 58
years (range 39–75 years). The patient characteristics are
summarized in Table 1. 14 patients had clear cell histol-
ogy, one patient had clear cell with sarcomatoid features
and 4 patients had clear cell carcinoma with papillary
features. 15 had visceral/bone metastases. 17 patients had
prior nephrectomy and 11 had prior immunotherapy.
Treatment summary
A total of seventy-six cycles of therapy were administered.
Median number of cycles received per patient were 2,











African American 2 (11)
Histology
Clear cell 14 (74)
Papillary features 4 (21)











Immunotherapy + chemo 4 (21)
Metastatic sites
Visceral/Bone 15 (79)
Lymph node/Soft Tissue 4 (21)
with a range of 1 to 12 cycles. 4 patients required dose
reduction; 1 due to diarrhea and 3 due to ocular toxicity.
No treatment related hospitalizations and mortalities were
observed.
Toxicity
A comprehensive summary of toxicities is provided in
Table 2. There were no grade 4 or 5 toxicities. Therapy
was well tolerated with few severe toxicities consisting
Table 2. Toxicity profile
Toxicity Grade 1 Grade 2 Grade 3 Grade 4
Nyctalopia 0 5 0 0
Anemia 5 1 0 0
Ocular 1 7 0 0
Photophobia 1 1 0 0
Fatigue 5 3 1 0
Dermatologic -rash 0 2 0 0
Nausea 4 1 1 0
Vomiting 1 1 1 0
Diarrhea 3 1 1 0
Lymphopenia 2 1 0 0
Creatinine 1 2 0 0
Thrombosis 0 0 1 0
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of thrombosis in 1 patient, grade 2 anemia in 1 patient
and grade 3 fatigue, diarrhea and nausea in 1 patient. Five
patients had grade 2 nyctalopia and 3 patients had tran-
sient grade 2 visual toxicity. Four patients required dose
reduction; 3 due to grade 2 nyctalopia and 1 due to grade
2 diarrhea.
Response and survival
Eighteen patients were evaluable for response as one eligi-
ble patient died of progressive disease before starting the
fenretinide therapy. No objective responses were noted
in the evaluable patients. Stabilization of disease (DS)
was seen in 7 of 19 eligible patients (37%, 90% C.I.
0.21–0.59). Of the 14 patients with documented disease
progression prior to study entry, four had disease stabi-
lization with therapy. Median time to progression was
1.5 months and median duration of DS was 5.8 months
(90% C.I. 3.0–8.4 months) (Figure 1). DS rates at 3 and 6
months were 71% and 38% respectively. The median sur-
vival in this pretreated advanced renal cancer population
was 10 months (90% C.I. 6.4–16.9 months) (Figure 2).
The differences in survival and in progression-free sur-
vival by prior systemic therapy status were not statistically
significant (Table 3).
Figure 1. Kaplan-Meier estimate of stable disease duration. Dashed lines indicate 90% confidence limits.
Correlative studies
Four patients consented to the post therapy biopsy, and
no severe complications related to the biopsy procedure
were noted in these patients. HPLC analysis revealed de-
tectable intratumoral levels of fenretinide in three biopsy
specimens at 3.6 µM (1.4 mcg/g), 3.8 µM (1.5 mcg/g)
and 7.9 µM (3.1 mcg/g). In the remaining case, fenre-
tinide was detected in the biopsy, but its level was below
the limit of quantitation.
Discussion
Amongst the retinoids, 13-CRA was extensively evalu-
ated in renal cancer and the initial clinical results were en-
couraging with a response rate of 30% in a phase II study
in metastatic renal cancer [16]. In vitro studies demon-
strated that 13-CRA potentiated the effects of interferon
in interferon sensitive renal cancer cell lines [17]. Retinoic
acid receptor (RAR) beta was induced in retinoid sensitive
cell lines and probably mediated the anti-tumor efficacy
of 13-CRA [15]. The results of the randomized clinical
trial comparing interferon and 13-CRA [4] with inter-
feron alone demonstrated higher response rate (6% vs.
12%) with the combination but no statistically significant
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Figure 2. Kaplan-Meier estimate of overall survival of eligible patients. Dashed lines indicate 90% confidence limits.
difference in overall survival. However a higher propor-
tion of patients appeared to have longer durations of re-
sponse in 13-CRA arm. Hence a select population of renal
cancers that have RAR-beta induction and interferon sen-
sitivity will likely benefit from administration of retinoid
therapy.
Fenretinide is a synthetic retinoid that emerged pre-
clinically as a very active inducer of apoptosis indepen-
dent of retinoic acid receptor alpha expression such as
in HL-60R and NB-306 leukemia cell lines [17, 18]. At
concentrations of 5–20 micromoles fenretinide demon-
Table 3. Overall survival and time to progression by prior systemic
therapy status
Any prior systemic therapy
Endpoint Yes (n = 11) No (n = 8)
Overall survival
Median (mo.) 10.0 (6.4, 10.3) 7.9 (2.1, N/A)
6-month rate 65% (0.42, 0.89) 62% (0.34, 0.90)
12-month rate 34% (0.11, 0.58) 37% (0.08, 0.67)
Time to progression
Median (mo.) 1.4 (1.3, 1.8) 1.8 (0.8, 5.9)
3-month rate 25% (0.03, 0.46) 25% (0.00, 0.50)
6-month rate 8% (0.00, 0.21) 14% (0.00, 0.34)
Table entries are the point estimate of the survival statistic, with its
90% confidence limits shown underneath, in parentheses.
N/A = not available, due to censoring pattern and small sample size.
strated potent activation of retinoic acid receptor gamma
and moderate activation of the retinoic acid beta receptors.
Multiple other mechanisms of antiproliferative effects of
fenretinide have been described including generation of
free oxygen radicals and down regulation of c-myc, cyclin
D1 and p34 leading to apoptotic effect [17–20].
Clinical investigation of fenretinide has primarily been
conducted in breast cancer with prolonged administration
of lower doses for chemoprevention [21]. A large study in
54 children with neuroblastoma revealed that dose escala-
tion upto 4000 mg/m2 for 28 days administration was fea-
sible [22]. There was about a 10-fold difference in the peak
plasma levels with dose escalation from 100 mg/m2/day
to 4000 mg/m2daily. The 28-day administration caused
approximately 2-fold increase in the levels for each dose
when compared with the levels after 7 days administra-
tion (from 0.6 to 1.3 µM and from 6 to 12.9 µM). These
plasma concentrations have been shown to induce apop-
tosis in vitro in neuroblastoma cell lines.
However, the relationship between plasma and tissue
levels of fenretinide is poorly understood, so it is not clear
if achieving in vitro-active concentrations in the plasma
will result in similarly high drug exposure in tumor tissue.
To that end, our study provided an opportunity to examine
accumulated intratumoral levels of fenretinide by obtain-
ing tumor biopsies after seven days of twice daily admin-
istration. In the current study of the 1800 mg/m2 daily for
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seven days regimen, tumor fenretinide levels measured
12–22 h after the last dose ranged from 3.6 to 7.9 µM,
which approximated levels expected in the tumor after one
half-life (plasma half-life in Phase I patients was 8–14 h,
data not shown), assuming that drug freely distributes be-
tween plasma and tumor. However, the in vitro assays
of solid tumor lines [24–26], including neuroblastoma
lines [27], also reveal a requirement to maintain fenre-
tinide concentrations at 10 µM for a minimum of 72 h
to elicit 50–90% growth inhibition and apoptosis. Taken
together, these results indicate that the effective in vitro
concentration range of fenretinide in other human solid
tumor cell lines was reached in the renal tumors treated
in our study, sometime between third and fourth day of
therapy and intratumoral levels were fluctuating between
effective and ineffective concentrations for the remain-
der of the treatment period. To our knowledge there are
no reports of optimal therapeutic concentrations of fenre-
tinide levels in renal cancer cell lines. Hence it is unknown
whether the fenretinide levels found to be therapeutic in
lung, breast and cervix cancer cell lines would also be
effective in renal cancer. The levels that have been found
to be sub therapeutic in other cancers are suggestive of a
reason for the lack of any objective responses in the study
in advanced renal cancer.
In conclusion, fenretinide demonstrated disease stabi-
lization in seven patients, of which three had stable disease
lasting for at least 6 months. The study also indicates that
prolonged administration at higher doses is feasible and
well tolerated, and could be considered in combination
with other effective therapies. However, the data clearly
show that fenretinide as a single agent has unremarkable
activity in RCC, so any further clinical development of
this drug for RCC would require a strong scientific ratio-
nale and preferably also an improved dosage form that
will maintain intratumoral levels above 10 µM for 72
consecutive hours or longer.
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